2024
Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 101097upj0000000000000679. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosis
2023
Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factors